ArticleInfectious diseases and therapy2026
Prevalence of Respiratory Syncytial Virus in Adult Patients with Respiratory Illnesses in Low to Middle-Income Countries: A Systematic Review and Meta-Analyses.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is a gap in the understanding of the burden of respiratory syncytial virus (RSV) among adults in low, lower-middle, and upper-middle income countries, particularly with regard to up-to-date epidemiological data. Meta-analyses were conducted to determine pooled estimates of RSV prevalence among high-risk 18-59-year-old adults and ≥ 50-year-old adults with or without risk factors or comorbidities, who present with respiratory illnesses in low, lower-middle, and upper-middle income countries.
methodsUsing studies identified from a previously described systematic literature review, a random-effects model was used to determine pooled prevalence for each study population. Subgroup analyses and meta-regression were conducted using the moderator variables deemed most relevant a priori and a mixed-effects approach.
resultsPooled RSV prevalence estimates were 5.1% (95% confidence interval [CI] 3.9-6.6%) and 3.9% (95% CI 3.3-4.7%) across 33 studies in 18-59-year-old high-risk adults with respiratory illnesses and 66 studies in ≥ 50-year-old adults with respiratory illnesses, respectively. Subgroup analyses for 18-59-year-old high-risk adults found geography, study setting, and respiratory illness to collectively explain ~ 54% of the variation in RSV prevalence estimates. The diagnostic method for RSV was found to explain ~ 8% of the variation in RSV prevalence estimates in ≥ 50-year-old adults; no other factors explored via subgroup analyses for ≥ 50-year-old adults had a notable effect on variation. For both populations, a substantial level of residual heterogeneity was observed using Higgin's I
conclusionsOverall, there is a considerable disease burden associated with RSV among 18-59-year-old high-risk and ≥ 50-year-old adults with respiratory illnesses in low, lower-middle, and upper-middle income countries, highlighting the need for improved prevention programs for RSV in these populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.